Development of Autoantibodies in the TrialNet Natural History Study
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVE: Understanding the relationship between age and islet autoantibody (Ab) seroconversion can establish the optimal screening interval(s) to assess risk for type 1 diabetes, identify subjects who can participate in prevention trials, and determine associated costs. This study assessed the rates of seroconversion to glutamic acid decarboxylase positive (GAD65+), insulin positive (mIAA+), and insulinoma-associated protein 2 positive (ICA512+) in a large cohort of relatives of type 1 diabetes probands undergoing Ab rescreening in the TrialNet Natural History Study. RESEARCH DESIGN AND METHODS: Of 32,845 children aged <18 years screened for Abs, 1,287 (3.9%) were GAD65+, 778 (2.4%) were mIAA+, 677 (2.1%) were ICA512+, and 31,038 were Ab-negative. Ab-negative children were offered annual rescreening up to 18 years of age. Cox regression was used to estimate the risk for GAD65, mIAA, and ICA512 seroconversion. RESULTS: There were 205 children who seroconverted to GAD65+, 155 who seroconverted to mIAA+, and 53 who seroconverted to ICA512+ over 5.8 years of follow-up. The risk of mIAA (hazard ratio 0.89 [95% CI 0.85–0.92]) and GAD65 (0.96 [0.93–0.99]) seroconversion significantly decreased with increasing age (i.e., for each 1-year increase in age, the risk of seroconversion decreased by 11% [P < 0.0001] for mIAA and 4% [P = 0.04] for GAD65) across all ages. The cumulative Ab seroconversion was 2% for those <10 years of age versus 0.7% for those ≥10 years of age. CONCLUSIONS: The risk of development of islet Abs declines with increasing age in type 1 diabetes relatives. These data support annual screening for children <10 years of age and one additional screening in adolescence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Self-citationInsel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216
Self-citationCampbell‐Thompson, M., Wasserfall, C., Kaddis, J., Albanese‐O'Neill, A., Staeva, T., Nierras, C., Moraski, J., Rowe, P., Gianani, R., Eisenbarth, G., et al. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2316 · Cited by 236
Self-citationΒ cell dysfunction exists more than 5 years before type 1 diabetes diagnosis
Evans-Molina, C., Sims, E. K., DiMeglio, L. A., Ismail, H. M., Steck, A. K., Palmer, J. P., Krischer, J. P., Geyer, S., Xu, P., Sosenko, J. M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120877 · Cited by 116
“aAb status was assessed using procedures outlined previously in the Diabetes Antibody Standardization Program (25).”
MethodSelf-citationReversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study
Vehik, K., Lynch, K. F., Schatz, D. A., Akolkar, B., Hagopian, W., Rewers, M., She, J.-X., Simell, O., Toppari, J., Ziegler, A.-G., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0181 · Cited by 103
Self-citation
Metadata
- Authors
- Vehik, K., Beam, C. A., Mahon, J. L., Schatz, D. A., Haller, M. J., Sosenko, J. M., Skyler, J. S., Krischer, J. P., & for the TrialNet Natural History Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-08-19
- Volume
- 34
- Issue
- 9
- Pages
- 1897-1901
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2154626801
- Cited by
- 74
- References
- 0
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Autoantibodies in the TrialNet Natural History Study. https://app.cochat.ai/papers/10.2337/dc11-0560
- The paper
- Vehik, K., Beam, C. A., Mahon, J. L., Schatz, D. A., Haller, M. J., Sosenko, J. M., Skyler, J. S., Krischer, J. P., & for the TrialNet Natural History Study Group. (2011). Development of Autoantibodies in the TrialNet Natural History Study. Diabetes Care. https://doi.org/10.2337/dc11-0560
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.